Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Overview
Heparin-induced thrombocytopenia (HIT) is one of the most common side effects of heparin therapy. A number of thrombotic conditions need heparin therapy to reduce the risk of thrombosis. Further, the therapy has showed some success in reducing the morbidity and mortality associated with thrombotic conditions. Despite the marked success of the therapy, HIT has been a major cause of morbidity, leading to amputations. The drive for the HIT treatment market stems from this trend.
Some of the key areas where the market has made strides relate to cardiac catheterization labs, intensive care units, and cardiac surgery theaters. HIT treatments usually begin after a careful clinical assessment and detection of low platelet count, while the results of functional assay and immunoassays are awaited. Some of the most common assays used by clinicians are Serotonin Release Assay, PF4 ELISA, Heparin-Induced Platelet Activation Tests, and Enzyme Immunoassay. For example, clinical diagnosis with the 4T score is done using Serotonin Release Assay and PF4 ELISA.
The epidemiology of HIT is low: 5% of patients exposed to heparin products suffer with HIT, but due to high mortality rate, the HIT treatment market is expected to make large strides.
Are you a start-up willing to make it big in business? Grab an exclusive Sample for this report!
Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Competitive Analysis and Key Developments
The HIT treatment market has seen promising clinical advances on the back of constant updates in guidelines. American Society of Hematology (ASH) Guideline in 2018 has suggested various alternative anticoagulant options that clinicians can choose from. Current practice guidelines in developed nations have propelled new drugs that are thrombin inhibitors, and numerous immunoassays. This has expanded treatment options during acute HIT. Top players are aiming at unveiling new anticoagulants for enhancing healthcare team outcomes. Assay manufacturers and drug makers are leaning on reducing the risk of thromboembolic complications. Some of the well-known drugs are apixaban, rivaroxaban, dabigatran, bivalirudin, and fondaparinux.
Some of the promising players in the HIT treatment market are Celgene Corporation, Syntex S.A., Fresenius Kabi AG, Teva Pharmaceutical Industries Ltd., Sanofi S.A., Mylan N.V., LEO Pharma A/S, Eisai Co., Ltd, Bristol-Myers Squibb Company, Janssen Pharmaceuticals, Inc., and Pfizer Inc.
Do you want to assess potential implications of COVID-19 pandemic on your business and boost your preparedness? Grab an exclusive PDF Brochure for this report!
Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Key Trends
Growing awareness about heparin therapies made of bovine and porcine in clinical environment is a key trend bolstering the expansion of opportunities in the HIT treatment market. Advances in pathophysiology and clinical presentation and diagnosis of HIT are boosting the HIT treatment market. Progress in anticoagulant therapies has expanded new avenues. A key case in point is low-molecular-weight heparin.
Focus of players on improving the efficacy of assays has expended the clinical avenues in the HIT treatment market. PF4 ELISA is one of them that has attracted the attention of clinicians. Rising use of antigen assays for PF4 antibodies has also boosted the HIT treatment market. However, the lack of availability of advanced functional assays in hospitals has made diagnosis of HIT difficult.
Heparin-Induced Thrombocytopenia (HIT) Treatment Market: Regional Assessment
Some of the regional markets for HIT treatment can be North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. Of these, North America has witnessed considerable revenue prospects on the back of a robust lab infrastructure and rapidly rising research in anticoagulant therapies. The regional healthcare system has also seen benefits of pathophysiology. Growing awareness of the morbidity and mortality of heparin therapy in patients, particularly cardiac surgery theaters, has soured research in countries such as the U.S. Asia Pacific is expected to rise at promising potential over the forecast period of 2020 to 2030, expanding on the back of advances in assays used to detect HIT.
This study by TMR is all-encompassing framework of the dynamics of the market. It mainly comprises critical assessment of consumers' or customers' journeys, current and emerging avenues, and strategic framework to enable CXOs take effective decisions.
Our key underpinning is the 4-Quadrant Framework EIRS that offers detailed visualization of four elements:
- Customer Experience Maps
- Insights and Tools based on data-driven research
- Actionable Results to meet all the business priorities
- Strategic Frameworks to boost the growth journey
The study strives to evaluate the current and future growth prospects, untapped avenues, factors shaping their revenue potential, and demand and consumption patterns in the global market by breaking it into region-wise assessment.
The following regional segments are covered comprehensively:
- North America
- Asia Pacific
- Latin America
- The Middle East and Africa
The EIRS quadrant framework in the report sums up our wide spectrum of data-driven research and advisory for CXOs to help them make better decisions for their businesses and stay as leaders.
Below is a snapshot of these quadrants.
1. Customer Experience Map
The study offers an in-depth assessment of various customers’ journeys pertinent to the market and its segments. It offers various customer impressions about the products and service use. The analysis takes a closer look at their pain points and fears across various customer touchpoints. The consultation and business intelligence solutions will help interested stakeholders, including CXOs, define customer experience maps tailored to their needs. This will help them aim at boosting customer engagement with their brands.
2. Insights and Tools
The various insights in the study are based on elaborate cycles of primary and secondary research the analysts engage with during the course of research. The analysts and expert advisors at TMR adopt industry-wide, quantitative customer insights tools and market projection methodologies to arrive at results, which makes them reliable. The study not just offers estimations and projections, but also an uncluttered evaluation of these figures on the market dynamics. These insights merge data-driven research framework with qualitative consultations for business owners, CXOs, policy makers, and investors. The insights will also help their customers overcome their fears.
3. Actionable Results
The findings presented in this study by TMR are an indispensable guide for meeting all business priorities, including mission-critical ones. The results when implemented have shown tangible benefits to business stakeholders and industry entities to boost their performance. The results are tailored to fit the individual strategic framework. The study also illustrates some of the recent case studies on solving various problems by companies they faced in their consolidation journey.
4. Strategic Frameworks
The study equips businesses and anyone interested in the market to frame broad strategic frameworks. This has become more important than ever, given the current uncertainty due to COVID-19. The study deliberates on consultations to overcome various such past disruptions and foresees new ones to boost the preparedness. The frameworks help businesses plan their strategic alignments for recovery from such disruptive trends. Further, analysts at TMR helps you break down the complex scenario and bring resiliency in uncertain times.
The report sheds light on various aspects and answers pertinent questions on the market. Some of the important ones are:
1. What can be the best investment choices for venturing into new product and service lines?
2. What value propositions should businesses aim at while making new research and development funding?
3. Which regulations will be most helpful for stakeholders to boost their supply chain network?
4. Which regions might see the demand maturing in certain segments in near future?
5. What are the some of the best cost optimization strategies with vendors that some well-entrenched players have gained success with?
6. Which are the key perspectives that the C-suite are leveraging to move businesses to new growth trajectory?
7. Which government regulations might challenge the status of key regional markets?
8. How will the emerging political and economic scenario affect opportunities in key growth areas?
9. What are some of the value-grab opportunities in various segments?
10. What will be the barrier to entry for new players in the market?
Note: Although care has been taken to maintain the highest levels of accuracy in TMR’s reports, recent market/vendor-specific changes may take time to reflect in the analysis.